Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis.
Pentavalent antimony-mannan (Sb[V]-mannan) was 10-fold more potent than sodium stibogluconate in a murine model of visceral leishmaniasis. Liver antimony concentrations were six-fold higher after Sb[V]-mannan therapy compared with a dose of sodium stibogluconate that was equipotent in reducing liver parasite burdens. Murine toxicity of Sb[V]-mannan was variable, with a 50% lethal dose (LD50) for one preparation that was well above the concentration that killed 90% of the parasites, and for another preparation was only modestly higher than the concentration that killed 90% of the parasites.
Department of Pathology, University of Mississippi Medical Center, Jackson, USA.
W L
WL
Roberts
J
J
Hariprashad
P M
PM
Rainey
H W
HW
Murray
D000818:Animals; D000965:Antimony / Q000032:analysis; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004337:Drug Carriers; D007274:Injections, Intraperitoneal; D007893:Leishmania donovani / Q000187:drug effects / Q000302:isolation & purification; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008099:Liver / Q000737:chemistry / Q000469:parasitology; D008351:Mannans / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C
D000981:Antiprotozoal Agents; D004337:Drug Carriers; D008351:Mannans; D000965:Antimony; D000967:Antimony Sodium Gluconate